FDA accepts filing of New Drug Application investigational antidepressant, LY03005

LY03005 is a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI), with one of the active metabolites being a serotonin-norepinephrine reuptake inhibitor.

Biospace Inc.